Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer

被引：4
|
作者：
Fagin, James A. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Med, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 10期
关键词：
REARRANGEMENTS; CARCINOMA; CHILDREN;
D O I：
10.1200/JCO.21.02864
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1124 / +
页数：4
相关论文
共 50 条
  • [21] The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
    Verbeek, Hans H. G.
    Alves, Maria M.
    de Groot, Jan-Willem B.
    Osinga, Jan
    Plukker, John T. M.
    Links, Thera P.
    Hofstra, Robert M. W.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) : E991 - E995
  • [22] Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
    Lorusso, Loredana
    Pieruzzi, Letizia
    Biagini, Agnese
    Sabini, Elena
    Valerio, Laura
    Giani, Carlotta
    Passannanti, Paolo
    Pontillo-Contillo, Benedetta
    Battaglia, Valentina
    Mazzeo, Salvatore
    Molinaro, Eleonora
    Elisei, Rossella
    ONCOTARGETS AND THERAPY, 2016, 9 : 6467 - 6477
  • [23] Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer
    Meng, Lei
    Zhao, Pengxin
    Hu, Zhigang
    Ma, Weiyuan
    Niu, Yong
    Su, Jingwei
    Zhang, Yubo
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (03) : 596 - 602
  • [24] Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors
    Sandblom, Viktor
    Spetz, Johan
    Shubbar, Emman
    Montelius, Mikael
    Stahl, Ingun
    Swanpalmer, John
    Nilsson, Ola
    Forssell-Aronsson, Eva
    PLOS ONE, 2020, 15 (05):
  • [25] The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring
    Carhill, Aubrey A.
    Cabanillas, Maria E.
    Jimenez, Camilo
    Waguespack, Steven G.
    Habra, Mouhammed A.
    Hu, Mimi
    Ying, Anita
    Vassilopoulou-Sellin, Rena
    Gagel, Robert F.
    Sherman, Steven I.
    Busaidy, Naifa L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01) : 31 - 42
  • [26] Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin
    McDonell, Laura M.
    Kernohan, Kristin D.
    Boycott, Kym M.
    Sawyer, Sarah L.
    HUMAN MOLECULAR GENETICS, 2015, 24 : R60 - R66
  • [27] Tyrosine kinase inhibitors in patients with radioiodine-refractory, differentiated thyroid cancer Is there an optimal timepoint for their use?
    Rendl, Gundula
    Schweighofer-Zwink, Gregor
    Pirich, Christian
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2023, 16 (01): : 8 - 16
  • [28] Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer
    Felicetti, Francesco
    Nervo, Alice
    Piovesan, Alessandro
    Berardelli, Rita
    Marchisio, Filippo
    Gallo, Marco
    Arvat, Emanuela
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (12) : 1093 - 1098
  • [29] Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials
    Liu, Jen-Wei
    Chen, Chiehfeng
    Loh, El-Wui
    Chu, Chun-Cheng
    Wang, Mu-Yi
    Ouyang, Hsin-Ju
    Chang, Ya-Ting
    Zhuang, Wei-Zhan
    Chou, Ching-Wen
    Huang, Der-Jr
    Lee, Chia-Hwa
    Yen, Yun
    Tam, Ka-Wai
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 795 - 803
  • [30] Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer
    Chrisoulidou, Alexandra
    Mandanas, Stylianos
    Margaritidou, Efterpi
    Mathiopoulou, Lemonia
    Boudina, Maria
    Georgopoulos, Konstantinos
    Pazaitou-Panayiotou, Kalliopi
    ONCOTARGETS AND THERAPY, 2015, 8 : 2435 - 2442
12345